Metopirone (Metyrapone)

Metyrapone blocks the enzyme 11‑beta‑hydroxylase in the adrenal cortex, preventing the final step of cortisol synthesis. This reduces circulating cortisol levels and causes a buildup of precursor steroids, which can be measured during diagnostic tests or used therapeutically to control hypercortisolism.

The dose of Metopirone is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the appropriate amount based on the specific indication, patient characteristics, and laboratory monitoring results.

Safety data for Metopirone in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician after careful evaluation.

To order Metopirone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Metopirone is ketoconazole, another steroidogenesis inhibitor. While both reduce cortisol, ketoconazole also inhibits several other enzymes and may have a broader side‑effect profile, whereas Metopirone is more selective for 11‑beta‑hydroxylase, offering a different safety and efficacy balance.

Metopirone tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Metopirone is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless otherwise directed by a healthcare professional. Administration timing may be adjusted based on the therapeutic protocol and monitoring schedule.

Serious risks include adrenal crisis due to sudden cortisol deficiency, severe hypotension, allergic reactions such as rash or angioedema, hepatic dysfunction, significant electrolyte disturbances (e.g., hyponatremia), and hypoglycemia. Patients should be educated to seek immediate medical attention if these symptoms occur.

Metopirone is contraindicated in patients with known hypersensitivity to metyrapone or any excipients, in those with uncontrolled hypertension, and in individuals where cortisol suppression could be dangerous, such as patients with active infection or severe liver disease, unless a physician determines it is essential.